Livagen is a synthetic tetrapeptide classified as a Khavinson-class bioregulator targeted at liver and hepatocyte tissue, investigated for cytoprotective and anti-aging effects on hepatocellular gene expression and chromatin organization through proposed regulatory mechanisms analogous to other short Khavinson-class bioregulators. Like other Khavinson bioregulator peptides, livagen is proposed to modulate gene expression in target hepatocyte cells through epigenetic and transcriptional mechanisms, with tissue-specific targeting proposed to support hepatocyte function and liver regenerative capacity under conditions of aging-related cellular stress.

liver cell regeneration, hepatoprotection, immune restoration via liver, chromatin activation.

Research on Livagen primarily documents effects related to liver cell regeneration and hepatoprotection and immune restoration via liver and chromatin activation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For Livagen, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

1 provider in the directory currently offers Livagen.

Livagen is tracked across 4 research vendors on PeptideBase, with per-mg prices ranging $2.76–$3.25. This reflects research-use vendor pricing, not clinical or prescription costs.

This review examines the biological activities and transport mechanisms of ultrashort di- and tripeptides including livagen, documenting evidence for their immunomodulatory activity in lymphoid and hematopoietic tissues and transport via intestinal peptide transporters relevant to systemic bioavailability.